BioSpace announced on Apr. 24 that it has received the Jesse H. Neal Award for Best Government, Legislative and Regulatory Coverage from the Software Information Industry Association (SIIA), highlighting its reporting on policy developments affecting the biopharma industry under President Donald Trump and Health Secretary Robert F. Kennedy Jr.
The recognition comes at a time when political decisions have significantly impacted drug development and regulatory oversight in the United States, prompting BioSpace to focus more on policy reporting alongside its traditional coverage of pharmaceutical advancements.
In addition to the Neal Award, BioSpace also won a regional gold medal for Industry News Coverage in the 2026 Azbee Awards of Excellence. Both awards acknowledged BioSpace’s coverage of senior leadership turnover at the Food and Drug Administration (FDA), particularly following large-scale layoffs initiated by Elon Musk’s Department of Government Efficiency in April 2025. The publication's visualizations tracking FDA departures engaged over 300,000 people on LinkedIn, demonstrating strong reader interest.
BioSpace was further commended for its reporting on communication issues within the FDA. Capricor CEO Linda Marbán told reporter Heather McKenzie, “When you run a public company, you have to be able to respond when the investors call you, and so if you don’t know first, you really are sort of put off your game.”
Another topic earning recognition was Congress’s failure to reauthorize the rare pediatric disease priority review program at the end of 2024. Stacey Frisk, executive director of the Rare Disease Company Coalition (RDCC), said in early 2025 that “the impact on rare disease drug developers and the investment community [is] already being felt because of the destabilizing effect of the failure to reauthorize.” According to BioSpace’s analysis accompanying this story, companies disclosed spending $513 million on priority review vouchers earned in 2024 alone.
SIIA also cited BioSpace’s coverage of cell and gene therapy developments as well as editorials addressing Kennedy's positions regarding vaccines and mRNA technology as reasons for making them finalists in Best Industry Coverage and Best Commentary categories.
Lori Ellis shared her appreciation upon receiving news she would be honored with this year’s Marianne Dekker Mattera Mentor Award for mentorship in B2B journalism: “Your dedication to leading BioSpace‘s newsroom has set a standard for excellence in the industry.” Ellis credited her team members Heather McKenzie and Annalee Armstrong with producing much of BioSpace's award-winning work.
Looking ahead, Ellis said she anticipates continued high-quality reporting from an expanded editorial team that now includes Gabrielle Masson.
